About Aperiam Bio
Aperiam Bio is a Healthcare company based in United States founded in 2019. Industrial and therapeutic proteins are manufactured by Aperiam Bio. Aperiam Bio has raised $13 million across 2 funding rounds from investors including OMX Ventures, Civilization Ventures and Axial. Aperiam Bio offers products and services including Technical Reagents, Cosmetics Enzymes, and Pulmonary Biologics. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Drug Development. Its competitors include AmbioPharm, Ocelot Bio and vivitide; 2 of its 3 listed competitors have raised funding.
Company details
Aperiam Bio was founded in 2019 in the United States. Proteins for industrial and therapeutic uses are produced through biotechnology processes. Operations center on the development and manufacturing of these proteins for sector-specific needs. The company operates within the biotech industry, with a focus on protein-based solutions. Its online presence is maintained via aperiambio.com, supporting information on activities and contacts.
- Headquarters United States
- SectorsHealthcare
- Website aperiambio.com
- Social LinkedIn
- Total Equity Funding$13M (USD)
in 2 rounds
- Latest Funding Round$9M (USD), Seed
Nov 2023
- InvestorsOMX Ventures
& 3 more
Products & Services of Aperiam Bio
Aperiam Bio offers a comprehensive portfolio of products and services, including Technical Reagents, Cosmetics Enzymes, and Pulmonary Biologics.
Enables viable manufacturing of inaccessible proteins for partners.
Provides shelf-stable enzymes for new cosmetic actives applications.
Develops proteins that retain activity for medical nebulization uses.
Funding Insights of Aperiam Bio
Aperiam Bio has successfully raised a total of $13M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $9 million completed in November 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13M
- Total Rounds 2
- Last Round Seed — $9M
- First Round $4M
(Sep 2023)
- Investors Count 4
All 2 funding rounds of Aperiam Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2023 | $9M | Seed | – | OMX Ventures | |
| Sep 2023 | $4M | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in Aperiam Bio
Aperiam Bio has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include OMX Ventures, Civilization Ventures and Axial.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are made in transformative biotech companies by OMX Ventures. | omx.vc | Lincolnshire, USA | ||
Venture capital is provided to health tech and biology innovations. | civilizationventures.com | San Francisco, United States | ||
| axialvc.com | ||||
Early-stage investments are made in frontier science ventures. | kdtvc.com | Black Mountain, United States |
Investor details for Aperiam Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aperiam Bio
2 people are tracked at Aperiam Bio (2 in leadership).
| Name | Role | Group |
|---|---|---|
Austin Cole | Founder & CEO | Leadership |
Guillaume Cottarel | Founding Member - Head Of Platform | Leadership |
Complete people profiles for Aperiam Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aperiam Bio
3 dated milestones of Aperiam Bio across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Aperiam Bio is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Seed, of $9.0M.
Competitors of Aperiam Bio
Aperiam Bio has 3 listed competitors in our database, 2 of them funded. They include AmbioPharm, Ocelot Bio and vivitide.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ambiopharm.com | 2006 | North Augusta, United States | $24M | 186 | CDMO and analytical services for peptide development are provided. | |
| ocelotbio.com | 2020 | San Diego, United States | $36M | Ocelot Bio is a CDMO specializing in peptide manufacturing services. | ||
| vivitide.com | 1983 | Gardner, United States | 94 | Drug development services for neoantigen peptides and antibodies are provided. |
Detailed competitors of Aperiam Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Aperiam Bio (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aperiam Bio
Complete news archive for Aperiam Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aperiam Bio
Aperiam Bio was founded in 2019 and raised its 1st funding round 4 years after it was founded.
Aperiam Bio is headquartered in United States.
Aperiam Bio is a funded company, having raised a total of $13M across 2 funding rounds to date. The company's 1st funding round was a Seed of $4M, raised on Sep 2023.
Aperiam Bio was founded in 2019 in the United States. Proteins for industrial and therapeutic uses are produced through biotechnology processes. Operations center on the development and manufacturing of these proteins for sector-specific needs. The company operates within the biotech industry, with a focus on protein-based solutions. Its online presence is maintained via aperiambio.com, supporting information on activities and contacts.
Aperiam Bio's top competitors include AmbioPharm, vivitide and Ocelot Bio.
Aperiam Bio offers Technical Reagents, Cosmetics Enzymes, and Pulmonary Biologics.
Aperiam Bio has 4 investors. Key investors include OMX Ventures, Civilization Ventures, Axial, and KdT Ventures.